Previous 10 | Next 10 |
Inari Medical (NASDAQ:NARI) trades 2.9% down premarket after it commenced an underwritten public offering of 2M shares; underwriters granted 30-day option to purchase up to an additional 300K shares. Offer size, terms not yet decided. For further details see: Inari M...
IRVINE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the commencement of an underwri...
Penumbra has been posting strong revenue growth numbers, but the Street has not been rewarding the shares. The company still has not recovered the share it lost in stroke due to a product recall, but growth is accelerating and the Thunderbolt launch could drive a bigger shift. The...
IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the appointment of Mr. Robert Warner t...
Image source: The Motley Fool. Inari Medical, Inc. (NASDAQ: NARI) Q4 2021 Earnings Call Feb 23, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Inari Medical, Inc. (NARI) Q4 2021 Earnings Call Transcript
Inari Medical, Inc. (NARI) Q4 2021 Results Conference Call February 23, 2022 04:30 PM ET Company Participants Caroline Corner - IR Bill Hoffman - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Danielle Antalffy -...
Inari Medical press release (NASDAQ:NARI): Q4 GAAP EPS of $0.02 in-line. Revenue of $83.22M (+71.2% Y/Y) beats by $3.45M. Outlook: For the full year 2022, revenue of $350 million to $360 million, reflecting growth of approximately 26% to 30% over 2021. For further details see: Inari Med...
IRVINE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarte...
AAN, ACA, OTCPK:ACLLF, AEM, AEVA, AGI, AHT, ALLO, ALR, AMED, ANSS, ARNA, AZUL, BAND, BBDC, BBWI, BCSF, BHP, BIRD, BKNG, BMA, BMRN, CCRN, CDEV, CHDN, CHK, CLOV, CMLS, CPE, CSV, CTRA, CW, DHC, DK, DKL, EBAY, EFC, OTCPK:EIFZF, EVH, EXR, FBRT, FIVN, FIX, FLGT, FLS, FNF, FRG, FTI, FUBO, GBT, GH, G...
Inari Medical (NASDAQ:NARI) said the first patient was enrolled in a trial called PEERLESS, comparing the outcomes of patients with intermediate-high risk pulmonary embolism (PE) treated with the FlowTriever system versus catheter-directed thrombolysis (CDT). Pulmonary embolism is a bloc...
News, Short Squeeze, Breakout and More Instantly...
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024...
Hagens Berman Encourages NARI Investors with Substantial Losses to Contact Firm Before July 12, 2024 Deadline San Francisco, California--(Newsfile Corp. - June 26, 2024) - Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses no...
2024-06-01 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...